Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

About this update from Cingulate Inc.

[{"type":"image","alt":"Cingulate Inc.","displaySize":"","headline":null,"caption":"Cingulate Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/e62a6f953f929d09857897121e95d193"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lmh6sY4ewRXV2DZQkTXk7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e62a6f953f929d09857897121e95d193","width":300,"height":300}},"lazy":false},{"type":"text","content":"Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025","length":122,"tagName":"p"},{"type":"text","content":"Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone)","length":70,"tagName":"p"},{"type":"text","content":"KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate development of CTx-2103.","length":527,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 has been a very constructive one for Cingulate,” stated Chairman and CEO Shane J. Schaffer. “We held a productive meeting with the FDA last month and remain on target to file an NDA in the middle of the year for our lead ADHD asset CTx-1301. The results announced from a food effect study of 50mg CTx-1301 – our largest dose – were positive and consistent with previous fed/fast data (25mg CTx-1301). We were also pleased to receive a $3 million grant of non-dilutive funding for the development of CTx-2103 for the treatment of anxiety, advancing our pipeline and illustrating the applicability of Cingulate’s PTR™ platform.”","length":653,"tagName":"p"},{"type":"text","content":"Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application (NDA) for lead ADHD Asset CTx-1301 and Remains on Track to Submit the NDA Mid-2025 and Provides additional Clinical Updates","length":200,"tagName":"p"},{"type":"text","content":...

More updates from Cingulate Inc.